The Atlantic’s recent article, The New Old Age, marks a milestone for CoGenerate (formerly Encore.org), an indication of the uptake of ideas and language we’d been working to develop, implement and disseminate for more than a decade. Written by David Brooks,...
The Latest from CoGenerate
A new documentary film, Ink & Linda, chronicles the unexpected friendship between Inksap, a Vietnamese-American street artist in his 20s, and Linda, a white modern dance teacher in her 70s. Shortly after a chance encounter brings these two together, they begin...
We’re out to show the world that older and younger people can help solve pressing problems when they work together. To that end, today we’re launching the CoGen Challenge to Advance Economic Opportunity, a partnership with the Ares Charitable Foundation to elevate...
Daniel Luhata Shungu
Purpose Prize Fellow 2010
Shungu is working to purge onchocerciasis, a leading infectious cause of blindness, in the Democratic Republic of Congo through community-based distribution of medicine.
After a career with drug manufacturer Merck & Co., Daniel Luhata Shungu retired in 2002 to focus on eradicating onchocerciasis – also known as “river blindness” – a parasitic disease associated with irreversible blindness, severe itching, reduced life span, lizard-like skin and serious socioeconomic problems.
Seven million people are infected and approximately 70,000 are already blind or visually impaired in Shungu’s native Democratic Republic of Congo, where he is focusing his work. Once a person becomes blind, he or she becomes dependent on family members, especially children, who end up forgoing school to tend to their blind relatives.
Through training, capacity building and community empowerment, Shungu’s Lawrenceville, N.J.-based organization, United Front Against Riverblindness, is putting free medicine in the hands of local communities through designated community distributors who administer the drugs annually over a 10-year period to those affected. The distributors take personal responsibility for the success of the treatment and are in turn highly respected and recognized with gifts from their communities.
Nearly 1 million doses have been distributed so far. Early distribution success has encouraged Shungu to expand the efforts into new regions. Of his work, he says: “The satisfaction of realizing that the lives of many of the much less fortunate and previously helpless people in remote parts of Africa are being changed for the better is very hard to describe.”